Phenylthiohydantoin

"Phenylthiohydantoin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Thiohydantoin benzene derivative.

Descriptor ID	D010669
MeSH Number(s)	D03.383.129.308.432.555.868.650
Concept/Terms	Phenylthiohydantoin Phenylthiohydantoin

Below are MeSH descriptors whose meaning is more general than "Phenylthiohydantoin".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Azoles [D03.383.129]
Imidazoles [D03.383.129.308]
Imidazolidines [D03.383.129.308.432]
Hydantoins [D03.383.129.308.432.555]
Thiohydantoins [D03.383.129.308.432.555.868]
Phenylthiohydantoin [D03.383.129.308.432.555.868.650]

Below are MeSH descriptors whose meaning is related to "Phenylthiohydantoin".

Below are MeSH descriptors whose meaning is more specific than "Phenylthiohydantoin".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Phenylthiohydantoin" by people in this website by year, and whether "Phenylthiohydantoin" was a major or minor topic of these publications.

Bar chart showing 4 publications over 4 distinct years, with a maximum of 1 publications in 2015 and 2016 and 2025 and 2026

To see the data from this visualization as text, click here.

Year	Minor Topic	Total
2015	1	1
2016	1	1
2025	1	1
2026	1	1

Below are the most recent publications written about "Phenylthiohydantoin" by people in Profiles.

Jamroze A, Liu X, Hou S, Jess Li W, Yu H, Tracz A, Jacobi J, Li Q, Nastiuk K, Chen X, Huang J, Lin K, Liu M, Cai C, Lu Y, Puzanov I, Kirk JS, Chatta G, Tang DG. Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer. Signal Transduct Target Ther. 2026 May 01; 11(1).

View in: PubMed
Candelieri-Surette D, Cheranda N, Lee J, Teerlink CC, Pimentel C, Lynch JA, Berlowitz D, Schoen MW. The Impact of Race on Survival and Treatment in Veterans Treated for Metastatic Castration-Resistant Prostate Cancer. J Natl Compr Canc Netw. 2025 Dec; 23(12):507-515.

View in: PubMed
Santoni M, Massari F, Rizzo A, Mollica V, Cimadamore A, Montironi R, Battelli N. Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis. Tumori. 2023 Apr; 109(2):157-163.

View in: PubMed
Rizzo A, Oderda M, Mollica V, Merler S, Morelli F, Fragomeno B, Taveri E, Sorgentoni G, Santoni M, Massari F. A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents. Anticancer Drugs. 2022 01 01; 33(1):e43-e51.

View in: PubMed
Kohrt SE, Awadallah WN, Phillips RA, Case TC, Jin R, Nanda JS, Yu X, Clark PE, Yi Y, Matusik RJ, Anderson PD, Grabowska MM. Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells In Vitro. Mol Cancer Ther. 2021 02; 20(2):398-409.

View in: PubMed
Di Nunno V, Santoni M, Massari F. New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival? Eur Urol Oncol. 2019 07; 2(4):471.

View in: PubMed
Liu X, Han W, Gulla S, Simon NI, Gao Y, Cai C, Yang H, Zhang X, Liu J, Balk SP, Chen S. Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation. Oncotarget. 2016 Jan 12; 7(2):1754-64.

View in: PubMed
Ciccarese C, Santoni M, Brunelli M, Buti S, Modena A, Nabissi M, Artibani W, Martignoni G, Montironi R, Tortora G, Massari F. AR-V7 and prostate cancer: The watershed for treatment selection? Cancer Treat Rev. 2016 Feb; 43:27-35.

View in: PubMed
Hsieh CL, Botta G, Gao S, Li T, Van Allen EM, Treacy DJ, Cai C, He HH, Sweeney CJ, Brown M, Balk SP, Nelson PS, Garraway LA, Kantoff PW. PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Res. 2015 May 15; 75(10):1944-8.

View in: PubMed

People

Explore

Similar Concepts

Top Journals